ABOSAcumen Pharmaceuticals, Inc.

Nasdaq acumenpharm.com


$ 3.76 $ 0.02 (0.53 %)    

Wednesday, 15-May-2024 10:20:08 EDT
QQQ $ 448.97 $ 0.07 (0.02 %)
DIA $ 397.20 $ -0.70 (-0.18 %)
SPY $ 526.46 $ 0.54 (0.1 %)
TLT $ 91.80 $ -0.04 (-0.05 %)
GLD $ 218.62 $ -0.62 (-0.28 %)
$ 3.69
$ 3.74
$ 3.75 x 300
$ 3.78 x 100
$ 3.74 - $ 3.88
$ 1.81 - $ 11.31
231,158
na
220.71M
$ 0.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-27-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-28-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-acumen-pharmaceuticals-maintains-15-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 pri...

 acumen-pharmaceuticals-q1-2024-gaap-eps-025-beats-027-estimate

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate o...

 acumen-pharmaceuticals-says-first-patient-dosed-in-altitude-ad-a-phase-2-clinical-trial-of-sabirnetug-in-early-alzheimers-disease

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targ...

Core News & Articles

https://blog.tipranks.com/these-2-strong-buy-penny-stocks-are-poised-for-over-300-gains-say-analysts/  

 acumen-pharmaceuticals-presents-first-comprehensive-clinical-and-biomarker-data-for-sabirnetug-at-american-academy-of-neurology-2024-annual-meeting

Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker change...

 hc-wainwright--co-maintains-buy-on-acumen-pharmaceuticals-maintains-15-price-target

HC Wainwright & Co. analyst Andrew Fein maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 pric...

 acumen-pharmaceuticals-q4-eps-029-misses-026-estimate

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate...

 earnings-scheduled-for-march-26-2024

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

 acumen-pharmaceuticals-to-present-deeper-insights-including-fluid-biomarker-data-for-sabirnetug-during-emerging-science-session-at-the-american-academy-of-neurology-annual-meeting

- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (...

 acumen-pharmaceuticals-presents-sabirnetug-fluid-biomarker-target-engagement-analyses-from-phase-1-intercept-ad-study-in-early-alzheimers-at-adpd-2024-annual-meeting

Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug's downstream pharmacological effects in the...

 acumen-pharmaceuticals-to-present-sabirnetug-fluid-biomarker-and-target-engagement-analyses-from-phase-1-intercept-ad-study-in-early-alzheimers-at-the-adpd-2024-annual-meeting

-   Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD-   Poster...

 deutsche-bank-initiates-coverage-on-acumen-pharmaceuticals-with-buy-rating-announces-price-target-of-8

Deutsche Bank analyst Neena Bitritto-Garg initiates coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and a...

 acumen-pharmaceuticals-secures-500m-credit-facility-with-k2-healthventures

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical comp...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION